Ignite Creation Date:
2024-05-06 @ 3:41 AM
Last Modification Date:
2024-10-26 @ 11:37 AM
Study NCT ID:
NCT02345590
Status:
UNKNOWN
Last Update Posted:
2016-01-15
First Post:
2015-01-11
Brief Title:
Eplerenone in the Management of Abdominal Aortic Aneurysms
Sponsor:
Bayside Health
Organization:
Bayside Health
Study Overview
Official Title:
Eplerenone in the Management of Abdominal Aortic Aneurysms A Proof-Of-Concept Randomised Controlled Trial
Status:
UNKNOWN
Status Verified Date:
2016-01
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Weakening and expansion of the main abdominal artery abdominal aortic aneurysm AAA is a common problem in older Australians The majority of AAAs are small 55 mm and affect 90000 individuals in Australia and 45 million world-wide Currently the only treatment available for AAA is surgery However surgical therapies are not effective for small AAAs and these patients undergo a program of repeat imaging and consultation to monitor the size of the aneurysm and symptoms
This proposal is aimed at addressing the urgent need to identify a medical treatment able to limit progression of AAAs
The study design and rationale are based on strong preclinical evidence supporting the value of eplerenone an agent indicated for treatment of heart failure in limiting AAA progression If proved effective this medication would
1 Reduce the number of patients requiring costly surgery
2 Reduce the number of surgery related deaths and complications
3 Provide a therapy suitable for the rapidly expanding elderly age group who have AAAs
This proposal is aimed at addressing the urgent need to identify a medical treatment able to limit progression of AAAs
The study design and rationale are based on strong preclinical evidence supporting the value of eplerenone an agent indicated for treatment of heart failure in limiting AAA progression If proved effective this medication would
1 Reduce the number of patients requiring costly surgery
2 Reduce the number of surgery related deaths and complications
3 Provide a therapy suitable for the rapidly expanding elderly age group who have AAAs
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None